Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy biotech company and operator of the world’s first prediction markets-focused digital asset treasury centered on RAIN, today announced that it has initiated a process to voluntarily delist its ordinary shares, par value NIS 0.40 per share, from the Tel Aviv Stock Exchange.
In accordance with applicable Israeli law and the rules of the TASE, the last day the ordinary shares will trade on the TASE is expected to be April 23, 2026, and the ordinary shares are expected to be delisted from the TASE on or about April 26, 2026. Shareholders will be able to continue to buy and sell ordinary shares on the TASE in the same manner as has been the case to date until market close on the final day of trading.
The Company's ordinary shares will continue to trade on the NASDAQ Capital Market under the symbol "ENLV," and the Company will also continue to file public reports and disclosures in accordance with the rules and regulations promulgated by the U.S. Securities and Exchange Commission and NASDAQ
The delisting from the TASE will not affect Enlivex’s continued listing on Nasdaq in the United States, and all ordinary shares currently traded on the TASE may be transferred to NASDAQ.
ENLV began Friday up three cents, or 2.9%, to $1.08.
